StockData
Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc (IRWD) stock

IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3062% below fair value
$4.85+0.02 (+0.41%)

Close on Nov 16, 2026Market cap $801.41MP/E 6.3Yield –

Ironwood Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Ironwood Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $88.69M, down 16.3% year over year. For fiscal 2025 it was $95.14M, down 14.6% from the year before. Over ten years it grew -1.3% a year on average. The highest annual figure on record is $139.49M in fiscal 2016.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$95.14M-14.6%
FY2024Dec 31, 2024$111.42M-4.0%
FY2023Dec 31, 2023$116.09M+162.3%
FY2022Dec 31, 2022$44.27M-37.1%
FY2021Dec 31, 2021$70.41M-20.1%
FY2020Dec 31, 2020$88.06M-23.5%
FY2019Dec 31, 2019$115.04M+13.8%
FY2018Dec 31, 2018$101.06M+14.7%
FY2017Dec 31, 2017$88.15M-36.8%
FY2016Dec 31, 2016$139.49M+28.3%
FY2015Dec 31, 2015$108.75M+6.7%
FY2014Dec 31, 2014$101.89M-0.5%
FY2013Dec 31, 2013$102.38M-9.8%
FY2012Dec 31, 2012$113.47M+31.8%
FY2011Dec 31, 2011$86.09M+11.2%
FY2010Dec 31, 2010$77.45M+1.8%
FY2009Dec 31, 2009$76.10M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.42M-4.1%
Q1 FY2026Mar 31, 2026$21.94M-20.0%
Q4 FY2025Dec 31, 2025$21.86M-13.9%
Q3 FY2025Sep 30, 2025$22.47M-24.7%
Q2 FY2025Jun 30, 2025$23.37M-23.1%
Q1 FY2025Mar 31, 2025$27.43M+6.3%
Q4 FY2024Dec 31, 2024$25.39M-28.8%
Q3 FY2024Sep 30, 2024$29.83M-9.6%
Q2 FY2024Jun 30, 2024$30.39M-12.1%
Q1 FY2024Mar 31, 2024$25.82M+100.9%
Q4 FY2023Dec 31, 2023$35.68M+241.5%
Q3 FY2023Sep 30, 2023$32.99M+185.7%
Q2 FY2023Jun 30, 2023$34.58M+201.9%
Q1 FY2023Mar 31, 2023$12.85M+18.7%
Q4 FY2022Dec 31, 2022$10.45M-67.2%
Q3 FY2022Sep 30, 2022$11.55M+5.8%
Q2 FY2022Jun 30, 2022$11.45M-5.8%
Q1 FY2022Mar 31, 2022$10.82M-30.1%
Q4 FY2021Dec 31, 2021$31.85M+95.8%
Q3 FY2021Sep 30, 2021$10.91M-49.7%
Q2 FY2021Jun 30, 2021$12.16M-44.9%
Q1 FY2021Mar 31, 2021$15.48M-44.8%
Q4 FY2020Dec 31, 2020$16.27M-38.7%
Q3 FY2020Sep 30, 2020$21.69M-21.3%
Q2 FY2020Jun 30, 2020$22.08M-23.2%
Q1 FY2020Mar 31, 2020$28.03M-13.0%
Q4 FY2019Dec 31, 2019$26.54M-6.0%
Q3 FY2019Sep 30, 2019$27.55M-5.5%
Q2 FY2019Jun 30, 2019$28.76M+24.0%
Q1 FY2019Mar 31, 2019$32.20M-11.8%
Q4 FY2018Dec 31, 2018$28.24M-29.6%
Q3 FY2018Sep 30, 2018$29.16M-21.3%
Q2 FY2018Jun 30, 2018$23.19M-37.9%
Q1 FY2018Mar 31, 2018$36.51M+8.3%
Q4 FY2017Dec 31, 2017$40.12M+4.4%
Q3 FY2017Sep 30, 2017$37.07M-1.2%
Q2 FY2017Jun 30, 2017$37.34M–
Q1 FY2017Mar 31, 2017$33.70M–
Q4 FY2016Dec 31, 2016$38.44M–
Q3 FY2016Sep 30, 2016$37.53M–

More Ironwood Pharmaceuticals figures

See a number that looks wrong?